150 related articles for article (PubMed ID: 3781341)
21. Predictive value of serum CA125 following optimal cytoreductive surgery during weekly cisplatin induction therapy for advanced ovarian cancer.
Hempling RE; Piver MS; Natarajan N; Baker TR; Thompson JM; Hicks ML; Mettlin CJ
J Surg Oncol; 1993 Sep; 54(1):38-44. PubMed ID: 8377503
[TBL] [Abstract][Full Text] [Related]
22. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
23. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
Levenback C; Burke TW; Silva E; Morris M; Gershenson DM; Kavanagh JJ; Wharton JT
Gynecol Oncol; 1992 Sep; 46(3):317-21. PubMed ID: 1526508
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
[TBL] [Abstract][Full Text] [Related]
25. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
26. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer.
Bertelsen K; Hansen MK; Pedersen PH; Larsen G; Nyland M; Jacobsen M; Andersen JE
Br J Obstet Gynaecol; 1988 Dec; 95(12):1231-6. PubMed ID: 3224088
[TBL] [Abstract][Full Text] [Related]
27. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study.
Creasman WT; Omura GA; Brady MF; Yordan E; DiSaia PJ; Beecham J
Gynecol Oncol; 1990 Dec; 39(3):239-43. PubMed ID: 2258063
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
30. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
31. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma.
Baker TR; Piver MS; Hempling RE
Cancer; 1994 Jul; 74(2):656-63. PubMed ID: 8033045
[TBL] [Abstract][Full Text] [Related]
32. Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma.
Shelley WE; Carmichael JC; Brown LB; Fraser RC; Kirk ME; Krepart GV; Levitt M; Roy M; Willan AR; Wilson KS
Gynecol Oncol; 1988 Feb; 29(2):208-21. PubMed ID: 3338672
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma.
Smith MR; Peters WA; Drescher CW
Am J Obstet Gynecol; 1994 Jun; 170(6):1677-81; discussion 1681-2. PubMed ID: 8203425
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center.
Wils J; van Geuns H
Am J Clin Oncol; 1989 Jun; 12(3):251-4. PubMed ID: 2658540
[TBL] [Abstract][Full Text] [Related]
35. Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay.
Stratton JA; Mannel RS; Rettenmaier MA; Berman ML; DiSaia PJ
Gynecol Oncol; 1989 Jan; 32(1):55-9. PubMed ID: 2535831
[TBL] [Abstract][Full Text] [Related]
36. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
[TBL] [Abstract][Full Text] [Related]
37. Twice-daily, split-course abdominopelvic radiation therapy after chemotherapy and positive second-look laparotomy for epithelial ovarian carcinoma.
Eifel PJ; Gershenson DM; Delclos L; Wharton JT; Peters LJ
Int J Radiat Oncol Biol Phys; 1991 Sep; 21(4):1013-8. PubMed ID: 1917596
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
39. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look.
Ojeda-González MB; Alvárez-López I; Alonso-Muñoz MC; Badía-Serra J; Delgado-Latre E; de Andrés-Basauri L; López-López JJ
Oncology; 1991; 48(1):7-12. PubMed ID: 1987501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
